Archives of Gerontology and Geriatrics
Volume 51, Issue 1 , Pages 81-85 , July 2010

Chromogranin A (CgA) serum level as a marker of progression in hepatocellular carcinoma (HCC) of elderly patients

  • Michele Malaguarnera

      Affiliations

    • Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
    • ,
  • Marco Vacante

      Affiliations

    • Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
    • ,
  • Rosangela Fichera

      Affiliations

    • Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
    • ,
  • Alessandro Cappellani

      Affiliations

    • Department of Surgery of “Policlinico Gaspare Rodolico”, University of Catania, Via Santa Sofia 86, I-95123 Catania, Italy
    • ,
  • Erika Cristaldi

      Affiliations

    • Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
    • ,
  • Massimo Motta

      Affiliations

    • Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 095 726 2050; fax: +39 095 498 811.

Received 29 April 2009 ,Revised 10 August 2009 ,Accepted 13 August 2009.

References 

  1. Billingsley KG, Jarnagin WR, Fong Y, Blumgart LH. Segment-oriented hepatic resection in the management of malignant neoplasms of the liver. J. Am. Coll. Surg. 1998;187:471–481
  2. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate. 1996;28:98–106
  3. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  4. Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR, et al. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology. 2000;47:1654–1658
  5. Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr. Rev. 1991;12:181–187
  6. Ebara M, Ohto M, Watanabe Y, Kimura K, Saisho H, Tsuchiya Y, et al. Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology. 1986;159:371–377
  7. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–S34
  8. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O’Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine. 1991;70:33–45
  9. Iacangelo AL, Eiden LE. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul. Pept. 1995;58:65–88
  10. Ishak KG. New developments in diagnostic liver pathology. Monogr. Pathol. 1987;28:223–373
  11. Kouroumalis EA. Octreotide for cancer of the liver and biliary tree. Chemotherapy. 2001;47:150–161
  12. Landsberg L. Chromogranin A. N. Engl. J. Med. 1984;311:794–795
  13. Malaguarnera M, Cristaldi E, Cammalleri L, Colonna V, Lipari H, Capici A, et al. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch. Gerontol. Geriatr. 2009;48:213–217
  14. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 2002;36:410–417
  15. Nobles FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J. Clin. Endocrinol. Metab. 1997;82:2622–2628
  16. Nobles FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur. J. Clin. Invest. 1998;28:431–440
  17. O’Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N. Engl. J. Med. 1986;314:1145–1151
  18. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Watanabe K, et al. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer. 1999;85:812–818
  19. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, et al. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J. Gastroenterol. Hepatol. 2001;16:1290–1296
  20. Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur. J. Endocrinol. 2005;152:443–448
  21. Poon TC, Mok TS, Chan AT, Chan CM, Leong V, Tsui SH, et al. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clin. Chem. 2002;48:1021–1027
  22. Portel-Gomes GM, Grimelius L, Johansson H, Wilander E, Stridsberg M. Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am. J. Surg. Pathol. 2001;25:1261–1267
  23. Ranno S, Motta M, Rampello E, Risino C, Bennati E, Malaguarnera M. The chromogranin-A (CgA) in prostate cancer. Arch. Gerontol. Geriatr. 2006;43:117–126
  24. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin SST-2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J. Clin. Endocrinol. Metab. 2000;85:3882–3891
  25. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 2001;28:836–846
  26. Roskams T, Willems M, Campos RV, Drucker DJ, Yap SH, Desmet VJ. Parathyroid hormone-related peptide expression in primary and metastatic liver tumours. Histopathology. 1993;23:519–525
  27. Sherman M. Hepatocellular carcinoma. Gastroenterologist. 1995;3:55–66
  28. Shimizu A, Shiraki K, Ito T, Sugimoto K, Sakai T, Ohmori S, et al. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepato-cellular carcinoma in patients with cirrhosis. Int. J. Mol. Med. 2002;9:245–250
  29. Shinagawa T, Ohto M, Kimura K, Tsunetomi S, Morita M, Saisho H, et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography. A study in 51 patients. Gastroenterology. 1984;86:495–502
  30. Szende B, Horvath A, Bokonyi G, Keri G. Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. Br. J. Cancer. 2003;88:132–136
  31. Taupenot L, Harper KL, O’Connor DT. The chromogranin–secretogranin family. N. Engl. J. Med. 2003;348:1134–1149
  32. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 2001;34:603–605
  33. Tropea F, Baldari S, Restifo G, Fiorillo MT, Surace P, Herberg A. Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours. Clin. Drug Invest. 2006;26:715–722
  34. Tsai TJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery. 2000;127:603–608
  35. Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J. Gastroenterol. 2005;11:6115–6119
  36. Watkinson A, Dockray GJ. Functional control of chromogranin A and B concentrations in the body of the rat stomach. Regul. Pept. 1992;40:51–61
  37. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther. 1993;60:245–264
  38. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology. 1993;18:990–997
  39. Wiedenmann B, Huttner WB. Synaptophysin and chromogranins/secreto-granins–widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows. Arch. B. Cell. Pathol. Incl. Mol. Pathol. 1989;58:95–121
  40. Wilander E, Lundqvist M, Oberg K. Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects. Progr. Histochem. Cytochem. 1989;19:1–88
  41. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45:938–947
  42. Zhao M, Laissue JA, Zimmermann A. Neuroendocrine” differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol. Histopathol. 1993;8:617–626

PII: S0167-4943(09)00182-4

doi: 10.1016/j.archger.2009.08.004

Archives of Gerontology and Geriatrics
Volume 51, Issue 1 , Pages 81-85 , July 2010

Article Tools

* Image Usage & Resolution